If you were to buy the land and try to create something like this today, it would take years and cost probably double the asking price,” the listing broker said.

From ETFs to interval funds to applications for dual-share mutual funds/ETFs, the shutdown will delay the availability of new ...

Kimberly-Clark is buying Tylenol maker Kenvue in a cash and stock deal worth about $48.7 billion, creating a massive consumer health goods company.